- Home
- PBT vs TRVI Comparison
PBT vs TRVI Comparison
Compare PBT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- TRVI
- Stock Information
- Founded
- PBT 1980
- TRVI 2011
- Country
- PBT United States
- TRVI United States
- Employees
- PBT N/A
- TRVI N/A
- Industry
- PBT Oil & Gas Production
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- TRVI Health Care
- Exchange
- PBT Nasdaq
- TRVI Nasdaq
- Market Cap
- PBT 835.7M
- TRVI 725.7M
- IPO Year
- PBT N/A
- TRVI 2019
- Fundamental
- Price
- PBT $18.49
- TRVI $7.96
- Analyst Decision
- PBT
- TRVI Strong Buy
- Analyst Count
- PBT 0
- TRVI 9
- Target Price
- PBT N/A
- TRVI $20.72
- AVG Volume (30 Days)
- PBT 139.9K
- TRVI 3.1M
- Earning Date
- PBT 01-01-0001
- TRVI 11-05-2025
- Dividend Yield
- PBT 2.93%
- TRVI N/A
- EPS Growth
- PBT N/A
- TRVI N/A
- EPS
- PBT 0.35
- TRVI N/A
- Revenue
- PBT $18,413,820.00
- TRVI N/A
- Revenue This Year
- PBT N/A
- TRVI N/A
- Revenue Next Year
- PBT N/A
- TRVI N/A
- P/E Ratio
- PBT $51.70
- TRVI N/A
- Revenue Growth
- PBT N/A
- TRVI N/A
- 52 Week Low
- PBT $8.01
- TRVI $2.36
- 52 Week High
- PBT $18.80
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- PBT 69.58
- TRVI 51.91
- Support Level
- PBT $17.61
- TRVI N/A
- Resistance Level
- PBT $18.80
- TRVI $9.92
- Average True Range (ATR)
- PBT 0.65
- TRVI 0.73
- MACD
- PBT -0.01
- TRVI -0.24
- Stochastic Oscillator
- PBT 87.60
- TRVI 80.24
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.